# OnCo record cam2029 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cam2029/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cam2029" ;
  schema:name "CAM2029 (octreotide subcutaneous depot)"@en ;
  schema:description "CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations."@en ;
  schema:url <https://onco.cc/drugs/cam2029/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=CAM2029%20(octreotide%20subcutaneous%20depot)> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/camurus/> ;
  onco:trials <https://onco.cc/trials/nct05050942/> .